/Management
Management2018-07-15T04:00:25+00:00
Management
Scientific Advisory Board

Management

The Cloudbreak Therapeutics management team contains over 50 years of combined experience with ocular drug discovery and development. In addition, Cloudbreak Therapeutics is supported by seasoned advisers and consultants. Our business model is to repurpose approved systemic drugs for ocular delivery to treat eye diseases, to quickly advance drug candidates to complete proof-of-concept (POC) phase II clinical trials and to out-license global rights for phase III clinical trials, product registration and commercialization.

Jinsong Ni, Ph.D, Founder, Chief Executive Officer, Chief Scientific Officer

Dr. Jinsong Ni has over twenty years of pharmaceutical industry and academic research experience in drug discovery and drug development.

Prior to founding Cloudbreak Therapeutics, Dr. Ni was Scientific Director at Allergan for 15 years and Senior Scientist at Wyeth/Pfizer for 3 years. During his tenures at Allergan and Wyeth/Pfizer, Dr. Ni has been:

  • Member of project teams for the successful launch of many ocular and dermal products, including AlphaganP®, Combigan®, Lumigan®, Tazorac® and Ozurdex®
  • Member of scientific teams for marketing support of Lumigan®, Allergan P® and Ozurdex®
  • Member of scientific teams for the successful legal defense of billion dollar franchise products Lumigan® and Restasis® at Allergan and multi-billion dollar franchise product Premarin® at Wyeth

Dr. Ni has served as non-clinical subteam lead and compound manager to advance numerous drug candidates to various development stages including IND and NDA submission for small and large molecule drugs across multiple therapeutic areas including CNS (neuropathic pain), ophthalmology (glaucoma, ocular surface disease and retinal disease) and dermatology (actinic keratosis, acne, rosacea), womens’ health, oncology and infectious disease.Dr. Ni is Vice Chairman and a member of the Board of Directors of the Sino-America Biotechnology and Pharmaceutical Professional Association (SABPA) and President of SABPA’s Los Angeles/Orange County chapter. Dr. Ni is also a co-founder of an in-vitro diagnostic company in China working to successfully develop and launch its first commercial product.

Dr. Ni obtained his B.Sc. from Nanjing University, M.Sc. from Brock University, Ph.D. from University of Toronto and performed his Post-doctoral fellowship at the University of Utah.

Van Dinh, MBA, Co-founder, Chief Operating Officer

Van Dinh is the co-founder and Chief Operating Officer of Cloudbreak Therapeutics. Mr. Dinh has more than twenty years’ ‘experience in the pharmaceutical industry.

He has worked in different scientific disciplines such as pharmacokinetics, toxicology, pharmaceutical development and analytical sciences and gained a vast amount of experience in drug development processes. During 18 years with Allergan he was involved in many drug development projects and helped to bring many drug development projects to successful commercial approvals such as Lumigan®, Combigan®, Acuvail®, Zymaxid®, Tazorac®, Ozudex®, Alphagan P®, Restasis®, Latisse®, and Lastacaft®. While at Allergan he managed departments such as In Vivo Science, Scientific Operations and Formulations and Analytical Sciences.

Mr. Dinh obtained a Master of Business Administration degree from Webster University and a Bachelor’s degree in Chemistry from the University of California, Irvine.

Rong Yang, Ph.D, Head of Research

Dr. Yang joined Cloudbreak Therapeutics in May, 2016. He serves as the Head of Research of the company. Before joining Cloudbreak, Dr. Yang had 16 years of drug discovery and development experience with expertise in pharmacology.

He worked in the fields of ophthalmology, dermatology and neurosciences at the specialty pharmaceutical company Allergan. During this time, he led multidisciplinary teams and collaborated with other companies. Dr. Yang participated in several drug development projects including the Taz microsphere project (reached phase I), the PDE project (reached early development) and the GABA modulator project (reached phase II).

Dr. Yang holds a Ph.D. in biochemistry from the University of Wisconsin-Madison, a B.Sc. in biology from Peking University, and performed the post-doctoral fellowship at University of California, Los Angeles, Cancer Center.